Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

436 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Two cases of immune thrombocytopenia associated with pembrolizumab.
Le Roy A, Kempf E, Ackermann F, Routier E, Robert C, Turpin A, Marabelle A, Mateus C, Michot JM, Lambotte O. Le Roy A, et al. Among authors: lambotte o. Eur J Cancer. 2016 Feb;54:172-174. doi: 10.1016/j.ejca.2015.10.073. Epub 2015 Dec 10. Eur J Cancer. 2016. PMID: 26687374 No abstract available.
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.
Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, Cauquil C, Chanson P, Collins M, Durrbach A, Ederhy S, Feuillet S, François H, Lazarovici J, Le Pavec J, De Martin E, Mateus C, Michot JM, Samuel D, Soria JC, Robert C, Eggermont A, Marabelle A. Champiat S, et al. Among authors: lambotte o. Ann Oncol. 2016 Apr;27(4):559-74. doi: 10.1093/annonc/mdv623. Epub 2015 Dec 28. Ann Oncol. 2016. PMID: 26715621 Free article. Review.
Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O. Michot JM, et al. Among authors: lambotte o. Eur J Cancer. 2016 Feb;54:139-148. doi: 10.1016/j.ejca.2015.11.016. Epub 2016 Jan 5. Eur J Cancer. 2016. PMID: 26765102 Review.
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.
Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, Lanoy E, Texier M, Libenciuc C, Eggermont AM, Soria JC, Mateus C, Robert C. Boutros C, et al. Among authors: lambotte o. Nat Rev Clin Oncol. 2016 Aug;13(8):473-86. doi: 10.1038/nrclinonc.2016.58. Epub 2016 May 4. Nat Rev Clin Oncol. 2016. PMID: 27141885 Review.
Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy.
Le Burel S, Champiat S, Routier E, Aspeslagh S, Albiges L, Szwebel TA, Michot JM, Chretien P, Mariette X, Voisin AL, Lambotte O. Le Burel S, et al. Among authors: lambotte o. Ann Rheum Dis. 2018 Mar;77(3):468-470. doi: 10.1136/annrheumdis-2016-210820. Epub 2017 Feb 27. Ann Rheum Dis. 2018. PMID: 28242618 No abstract available.
Immune-related bone marrow failure following anti-PD1 therapy.
Michot JM, Vargaftig J, Leduc C, Quere G, Burroni B, Lazarovici J, Champiat S, Ribrag V, Lambotte O. Michot JM, et al. Among authors: lambotte o. Eur J Cancer. 2017 Jul;80:1-4. doi: 10.1016/j.ejca.2017.04.004. Epub 2017 May 17. Eur J Cancer. 2017. PMID: 28527392 No abstract available.
436 results